Forte Biosciences (FBRX) Stock Price, News & Analysis

Company Overview

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies for inflammatory and immune-mediated skin diseases. The company’s approach involves using naturally occurring microorganisms and their biological effects to help restore healthy skin function and address disease-related inflammation.

Forte’s lead product candidate has been FB-401, a topical live biotherapeutic product based on Roseomonas mucosa, a naturally occurring bacterium found on human skin. The program was developed primarily for the potential treatment of atopic dermatitis, a chronic inflammatory skin condition. Forte has evaluated FB-401 in clinical studies and has used the results to guide its research and development strategy.

Founded in 2016, Forte Biosciences is headquartered in Dallas, Texas. The company’s activities have primarily centered on developing therapies for dermatological and immune-related conditions, with its research directed toward patients in markets where these diseases represent significant unmet medical needs.

Key Stats

• Today's Range: $76.99 to $76.99
• 50-Day Range: $47.49 to $76.99
• 52-Week Range: $10.11 to $77.20
• Volume: N/A
• Average Volume: 1.86 million shs
• Market Capitalization: $1.63 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $71.67
• Consensus Rating: Hold

Forte Biosciences Stock Analysis - MarketRank™

Forte Biosciences scored higher than 7% of companies evaluated by MarketBeat, and ranked 870th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Forte Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 1 sell rating.

Downside Risk

Forte Biosciences has a consensus price target of $71.67, representing about 6.9% downside from its current price of $76.99.

Amount of Analyst Coverage

Forte Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Forte Biosciences are expected to decrease in the coming year, from ($4.27) to ($4.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Forte Biosciences is -16.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Forte Biosciences is -16.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Forte Biosciences has a P/B Ratio of 8.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for FBRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Forte Biosciences does not currently pay a dividend.

Dividend Growth

Forte Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for FBRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Forte Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.40% of the stock of Forte Biosciences is held by insiders.

Percentage Held by Institutions

77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/22/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FBRX
• CIK: 1419041
• Web: www.fortebiorx.com
• Phone: (310) 618-6994
• Fax: N/A
• Employees: 5
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Forte Biosciences: $71.67
• High Price Target: $77.00
• Low Price Target: $61.00
• Potential Upside/Downside: -6.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -94.82%
• Return on Assets: -77.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.01
• Quick Ratio: 10.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.66 per share
• Price / Book: 8.89

Miscellaneous

• Outstanding Shares: 21,229,000
• Free Float: 20,295,000
• Market Cap: $1.63 billion
• Optionable: Optionable
• Beta: 2.62